Hemostemix Closes Private Placement of $469,366

Rhea-AI Summary

Hemostemix (HMTXF) has closed a non-brokered private placement raising CAD $469,366 through the issuance of 3,911,385 common shares at CAD $0.12 per share, pending TSXV Exchange approval. The securities will have a four-month hold period from closing. The proceeds will support general working capital, operational expenses, and business development. Hemostemix is an autologous stem cell therapy company that has developed ACP-01, a blood-based stem cell therapy. The company has completed seven clinical studies with 318 subjects, with results published in nine peer-reviewed publications. Their Phase II clinical trial for chronic limb threatening ischemia showed promising results, including 0% mortality and 83% wound healing in patients followed for up to 4.5 years.

Positive

• Successful capital raise of CAD $469,366 to support operations and development
• Strong clinical trial results with 0% mortality rate compared to typical 60% mortality in CLTI patients
• Completed Phase II trial showing 83% wound healing success rate
• Extensive clinical experience with 7 studies and 318 subjects completed

Negative

• Dilution of existing shareholders through new share issuance
• Share price of CAD $0.12 indicates relatively low valuation
• Regulatory approvals still pending for various aspects of operations
• Ongoing need for external financing indicates cash flow challenges

Calgary, Alberta--(Newsfile Corp. - June 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces the closing of a non brokered private placement with in the amount of CAD $469,366 by the issuance of 3,911,385 Common Shares at CAD $0.12 each, subject to the approval of the TSXV Exchange. All securities issued in connection with the Offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.

Per Policy 4.1. the Subscriber is arm's length to the Company and is not a Related Party to the Company at the time of disclosure.

The use of proceeds will be allocated to general working capital purposes, supporting the Company's ongoing operational expenses and business development activities.

The Company confirms that there is no material fact or material change about the Company that has not been generally disclosed.

ABOUT HEMOSTEMIX

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in nine peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 60% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit www.hemostemix.com.

For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder

EM: tsmeenk@hemostemix.com PH: 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to sales of its lead product ACP-01, the commercialization of ACP-01 via the sale of compassionate treatments under Special Access Programs. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/255808

FAQ

What is the size and price of Hemostemix's (HMTXF) latest private placement?

Hemostemix closed a private placement of CAD $469,366 by issuing 3,911,385 common shares at CAD $0.12 per share.

What are the clinical trial results for Hemostemix's ACP-01 therapy?

The Phase II trial for chronic limb threatening ischemia showed 0% mortality, pain cessation, and 83% wound healing in patients followed for up to 4.5 years, compared to typical 60% mortality rates.

How many clinical studies has Hemostemix completed?

Hemostemix has completed seven clinical studies involving 318 subjects, with results published in nine peer-reviewed publications.

What will Hemostemix use the private placement proceeds for?

The proceeds will be used for general working capital purposes, supporting ongoing operational expenses, and business development activities.

What is the holding period for the newly issued Hemostemix shares?

The securities issued will be subject to a four-month hold period from the closing date under Canadian securities laws.